Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.53 - $1.14 $212 - $455
400 Added 13.33%
3,400 $2,000
Q3 2023

Nov 14, 2023

SELL
$0.84 - $1.43 $18,144 - $30,888
-21,600 Reduced 87.8%
3,000 $3,000
Q2 2023

Aug 14, 2023

BUY
$0.83 - $1.12 $2,075 - $2,800
2,500 Added 11.31%
24,600 $21,000
Q1 2023

May 15, 2023

BUY
$0.91 - $1.69 $91 - $169
100 Added 0.45%
22,100 $22,000
Q4 2022

Feb 14, 2023

BUY
$1.09 - $2.04 $11,881 - $22,236
10,900 Added 98.2%
22,000 $27,000
Q3 2022

Nov 14, 2022

BUY
$1.55 - $3.01 $17,205 - $33,411
11,100 New
11,100 $18,000

Others Institutions Holding FIXX

About Homology Medicines, Inc.


  • Ticker FIXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 57,402,000
  • Description
  • Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...
More about FIXX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.